Search - tctmd.com

Displaying 81 - 100 of 147

Sort: Relevancy | Date

Presentation TCT 2015

The MATRIX of Antithrombin Alternatives: Pros and Cons

Presenter: George D. Dangas, Paul A. Gurbel, Marco Valgimigli

October 13, 2015

News Conference News TCT 2015

EXPLORE: Treating CTOs After STEMI Does Not Improve LV Function

Todd Neale

October 13, 2015

Presentation TCT 2015

Bivalirudin vs Heparin in ACS: The New Data MATRIX Antithrombin Results

Presenter: John A. Bittl, Robert A. Harrington, Marco Valgimigli

October 12, 2015

Presentation TCT 2015

Periprocedural Antiplatelet Therapy: Agent(s) of Choice, Oral vs IV, and Loading Strategies

Presenter: Robert A. Harrington, Gregg W. Stone, David J. Cohen, Marco Valgimigli

October 12, 2015

Presentation TCT 2015

In Which Patients (if Any) Should BMS Be Used in 2015? Evidence and Common Sense

Presenter: John A. Bittl, E. Magnus Ohman, Marco Valgimigli

October 11, 2015

Presentation TCT 2015

Debate 2: Should Long-term (2 Years to Life) Dual Antiplatelet Therapy Be Used in Most Patients After MI? Slow Down, Excess Bleeding, and No Mortality Benefit? Primum Non Nocere and Save Costs!

Presenter: C. Michael Gibson, Marco Valgimigli, Tullio Palmerini

October 11, 2015

Presentation TCT 2015

Debate 2: Should Long-term (2 Years to Life) Dual Antiplatelet Therapy Be Used in Most Patients After MI? Yes, and Vorapaxar Should Be Considered!

Presenter: C. Michael Gibson, Marco Valgimigli, Ori Ben-Yehuda

October 11, 2015

Presentation TCT 2015

Debate 2: Should Long-term (2 Years to Life) Dual Antiplatelet Therapy Be Used in Most Patients After MI? Yes, and the Data Are Strong for Ticagrelor (PEGASUS Trial)!

Presenter: C. Michael Gibson, Marco Valgimigli, Neal S. Kleiman

October 11, 2015

Presentation TCT 2015

Debate 2: Should Long-term (2 Years to Life) Dual Antiplatelet Therapy Be Used in Most Patients After MI? Yes, and the Data Are Strong for Clopidogrel and Prasugrel (DAPT Trial)!

Presenter: C. Michael Gibson, Marco Valgimigli, Robert W. Yeh

October 11, 2015

Presentation TCT 2015

Debate 1: Should Cangrelor or an Oral ADP Antagonist Be Used in Most STEMI Patients? Prasugrel for Primary PCI Is Simplest and Best!

Presenter: C. Michael Gibson, Marco Valgimigli, Sigmund Silber

October 11, 2015

Presentation TCT 2015

Debate 1: Should Cangrelor or an Oral ADP Antagonist Be Used in Most STEMI Patients? Oral or Crushed Ticagrelor for All!

Presenter: C. Michael Gibson, Marco Valgimigli, Guido Parodi

October 11, 2015

Presentation TCT 2015

Debate 1: Should Cangrelor or an Oral ADP Antagonist Be Used in Most STEMI Patients? The Mechanism and Data Support Cangrelor!

Presenter: C. Michael Gibson, Marco Valgimigli, Harvey D. White

October 11, 2015

News Conference News ESC 2015

MATRIX Antithrombin: Bivalirudin Fails to Reduce Net Adverse Events vs Heparin in ACS Patients Undergoing PCI

Yael L. Maxwell

September 02, 2015

Presentation ESC 2015

Results From The Minimizing Adverse Haemorrhagic Events By Transradial Access Site And Systemic Implementation of Angiox-MATRIX Treatment Duration Program

Presenter: Marco Valgimigli

September 01, 2015

News Daily News

La Localización de la EAC Puede Influir en la Necesidad de Recibir Tratamiento Antiplaquetario Prolongado Post-PCI

Caitlin E. Cox

August 24, 2015

News Daily News

CAD的位置可影响PCI术后对延长DAPT的需求

Caitlin E. Cox

August 24, 2015

News Daily News

CAD Location May Influence Need for Prolonged DAPT Post-PCI

Caitlin E. Cox

August 24, 2015

News Conference News ACC 2015

MATRIX Provides Support for Radial Access, Mixed Results for Bivalirudin

Todd Neale

March 17, 2015

News Daily News

ZEUS发布：在“不确定”DES候选者中，带个性化DAPT的ZES胜过裸金属支架

L.A. McKeown

February 25, 2015

News Daily News

ZEUS Published: ZES With Personalized DAPT Bests Bare-Metal Stent in ‘Uncertain’ DES Candidates

L.A. McKeown

February 25, 2015

Advertisement

The MATRIX of Antithrombin Alternatives: Pros and Cons

EXPLORE: Treating CTOs After STEMI Does Not Improve LV Function

Bivalirudin vs Heparin in ACS: The New Data MATRIX Antithrombin Results

Periprocedural Antiplatelet Therapy: Agent(s) of Choice, Oral vs IV, and Loading Strategies

In Which Patients (if Any) Should BMS Be Used in 2015? Evidence and Common Sense

Debate 2: Should Long-term (2 Years to Life) Dual Antiplatelet Therapy Be Used in Most Patients After MI? Slow Down, Excess Bleeding, and No Mortality Benefit? Primum Non Nocere and Save Costs!

Debate 2: Should Long-term (2 Years to Life) Dual Antiplatelet Therapy Be Used in Most Patients After MI? Yes, and Vorapaxar Should Be Considered!

Debate 2: Should Long-term (2 Years to Life) Dual Antiplatelet Therapy Be Used in Most Patients After MI? Yes, and the Data Are Strong for Ticagrelor (PEGASUS Trial)!

Debate 2: Should Long-term (2 Years to Life) Dual Antiplatelet Therapy Be Used in Most Patients After MI? Yes, and the Data Are Strong for Clopidogrel and Prasugrel (DAPT Trial)!

Debate 1: Should Cangrelor or an Oral ADP Antagonist Be Used in Most STEMI Patients? Prasugrel for Primary PCI Is Simplest and Best!

Debate 1: Should Cangrelor or an Oral ADP Antagonist Be Used in Most STEMI Patients? Oral or Crushed Ticagrelor for All!

Debate 1: Should Cangrelor or an Oral ADP Antagonist Be Used in Most STEMI Patients? The Mechanism and Data Support Cangrelor!

MATRIX Antithrombin: Bivalirudin Fails to Reduce Net Adverse Events vs Heparin in ACS Patients Undergoing PCI

Results From The Minimizing Adverse Haemorrhagic Events By Transradial Access Site And Systemic Implementation of Angiox-MATRIX Treatment Duration Program

La Localización de la EAC Puede Influir en la Necesidad de Recibir Tratamiento Antiplaquetario Prolongado Post-PCI

CAD的位置可影响PCI术后对延长DAPT的需求

CAD Location May Influence Need for Prolonged DAPT Post-PCI

MATRIX Provides Support for Radial Access, Mixed Results for Bivalirudin

ZEUS发布：在“不确定”DES候选者中，带个性化DAPT的ZES胜过裸金属支架

ZEUS Published: ZES With Personalized DAPT Bests Bare-Metal Stent in ‘Uncertain’ DES Candidates

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content